Toronto, Ontario–(Newsfile Corp. – April 22, 2022) – Scryb Inc. (CSE: SCYB) (OTCQB: SCYRF) (FSE: EIY) (“Scryb” or the “Company”), is pleased to report that Cybeats has been recognized as a Representative Provider in the 2022 Gartner Innovation Insight for SBOMs[1] Report. Gartner, Inc. provides actionable objective insights, guidance, and tools that enable faster, smarter decisions and stronger performance on an organization’s most mission critical priorities.
Gartner Innovation Insight for SBOMs report stated, “SBOMs improve the visibility, transparency, security and integrity of proprietary and open-source code in software supply chains. To realize these benefits, software engineering leaders should integrate SBOMs throughout the software delivery life cycle.”
“With cyber attacks occurring on a much more frequent basis, we are seeing organizations across all industries ramping up their SBOM capabilities,” said Dmitry Raidman, CTO Cybeats. “Cybeats SBOM Studios solves software development teams’ cybersecurity challenges by: automating SBOMs for all software produced, verifying SBOMs for software consumed, and using SBOM data to continuously assess security and compliance risks before, during, and after deployment. SBOM Studio mitigates security and compliance risk in software allowing software engineers and developers to sleep at night!”
The Gartner report goes further and states:
“Software engineering leaders responsible for building software applications should:
We believe Cybeats SBOM STUDIO was named in this Gartner Report because it is known as a leading commercial SBOM tool and enterprise-class solution for manufacturing software applications – it effectively tracks the makeup of the software and assesses and identifies potential security risks. The software bill of materials is an inventory of every component of software that is included in an application. With over 90% of software applications developed using existing software components, organizations leave themselves open to many potential threats and vulnerabilities across their software supply chain.
Cybeats was also recognized in a second report, Gartner’s 2022 Market Guide for Medical Device Security Solutions, as a Representative Vendor in Medical Device Security. Cybeats SBOM STUDIO was listed as a top commercial SBOM tool and enterprise-class solution for software developers and consumers, with an innovative secure-by-design approach that uses both the IoT security platform and the SBOM Studio product suites.
SBOM Studio is an enterprise-class solution that tracks third-party components which are an integral part of software development. It automatically documents and tracks software components identifying where they were developed, potential security risks, and establishes a plan for the maintenance that will prevent security posture degradation over the life of the application. Software consumers or producers can use SBOM Studio to improve security and compliance, improve visibility and traceability of software, and improve data sharing.
Cybeats’ SBOM Studio includes key capabilities to improve cybersecurity during and after software application development:
Cybeats recently reported it has engaged trial deployments of its SBOM STUDIO product suite to multiple large organizations. The first is a multinational energy management company providing efficiency and sustainability for homes, buildings, and infrastructure across industries with over €25 billion in annual revenue. One organization is a noteworthy cryptocurrency exchange based in the U.S. and another is a ‘Big 5′ tech company. The organizations are using SBOM STUDIO to test the respective security of their software supply chain while improving compliance and reporting. The third company is a multinational IoT accessories company, which commenced a pilot engagement for its IoT security product suite. SBOM Studio will automate the tracking of third-party components which are an integral part of Cybeats’ client’s software development and provide developers with cloud-based reporting.
For more information on SBOM Studio, and to access the report, visit www.cybeats.com/gartner.
Gartner Disclaimer
*Gartner, “Innovation Insight for SBOMs”, Manjunath Bhat, Dale Gardner, Mark Horvath, Feb 14, 2022.
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved. Gartner does not endorse any vendor, product or service depicted in its research publications and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s Research & Advisory organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
RECENT NEWS: Scryb Recently Reported on Cybersecurity Trial Evaluation Engagement with Multinational Infrastructure Company: https://bit.ly/3MntyTP
About Cybeats
Cybeats delivers intelligent security applications for software supply chains and IoT connected devices, autonomously detecting and eliminating cyber risks from design to operation. Cybeats – Software Made Certain. Website: www.cybeats.com
Website: www.cybeats.com
SUBSCRIBE: For more information, or to SubScryb to the Company’s mail list, visit: https://www.scryb.ai
About Scryb
Scryb is a platform that powers businesses and technologies with applied intelligence, real-time analytics, and actionable insights. The platform boasts proven adaptability across diverse markets, from digital health and diagnostics to cybersecurity and manufacturing. The cloud-based platform is composed of crucial elements including sensor technology, IoT, predictive analytics, and computer vision.
For more information, please visit our website at: http://scryb.ai
Contact:
W. Clark Kent
President
Office. 647-872-9982
TF. 1-844-247-6633
Email: info@scryb.ai
Forward-Looking Information Cautionary Statement
Except for statements of historic fact, this news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company’s control. There are no assurances that the commercialization plans for the technology described in this news release will come into effect on the terms or time frame described herein. The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, which filings are available at www.sedar.com.
[1]https://www.gartner.com/en/documents/4011501-innovation-insight-for-sboms
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/121289
Marlborough, Massachusetts--(Newsfile Corp. - December 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage…
WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…
WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…
New leadership roles highlight Hallmark’s unique vendor-neutral approach to helping health systems build flexible, efficient,…
Company Celebrates Continued Worldwide Progress Toward Data-Driven Surgery SAN FRANCISCO and BERLIN, Dec. 23, 2024…
SEOUL, South Korea, Dec. 23, 2024 /PRNewswire/ -- Medit has launched a mobile app, MEDIT…